GlassScriptPhysician profile
Ikram Haq
NPI 1861427288
$2,101.98
in general payments reported to CMS, 2019-2025
18 companies · $665 in 2025
The $665 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $582 · 2020: $54.65 · 2021: $11.17 · 2022: $223 · 2023: $272 · 2024: $294 · 2025: $665.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,042 · Travel and Lodging: $190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,041.71 |
| Travel and Lodging | $190.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $705.67 | 2019-2025 | Dovato, Cabenuva |
| Insmed, INC. | $212.25 | 2019-2025 | Arikayce |
| Medtronic, INC. | $190.31 | 2025 | Micra |
| Abbott Laboratories | $162.14 | 2025 | Ensite |
| Theratechnologies INC. | $140.61 | 2023-2025 | Trogarzo, Egrifta |
| Melinta Therapeutics, LLC | $132.03 | 2019-2024 | Rezzayo, Vabomere, Kimyrsa |
| Merck Sharp & Dohme LLC | $127.42 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Allergan, INC. | $108.40 | 2019 | |
| Amgen INC. | $53.08 | 2022-2024 | Krystexxa |
| Octapharma USA, INC. | $51.36 | 2023-2025 | Panzyga |
| Aimmune Therapeutics, INC. | $47.39 | 2024-2025 | Vowst |
| Nevro Corp. | $40.85 | 2022 | |
| Abbvie INC. | $31.71 | 2022-2023 | |
| Horizon Therapeutics Plc | $24.84 | 2022 | |
| Glaxosmithkline, LLC. | $22.00 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $18.80 | 2019 | |
| Paratek Pharmaceuticals, INC. | $17.45 | 2022 | |
| Janssen Pharmaceuticals, INC | $15.67 | 2023 | Xarelto |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ikram Haq listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.